Applied Statistics

Antibodies: The Mayo Clinic

Total Score People Score Events Score
12 11 6
Date Event Presentation Speakers
January 31, 2013 5th Immunotherapeutics & Immunomonitoring The Immune System in Breast Cancer Initiation and Progression: Role of Epithelial to Mesenchymal Transition Keith Knutson
February 17, 2011 15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma Promising New Drugs in Clinical Trials in Myeloma Keith Stewart
CON Keith Stewart
How I Treat Myelofibrosis If No Clinical Trial Is Available Ruben A Mesa
Multiple Myeloma Keith Stewart
Chronic Myeloid Leukemia | Myeloproliferative Neoplasms Ruben A Mesa
August 21, 2009 Eighth International Congress on Targeted Therapies in Cancer Vascular Disrupting Agents Alex A Adjei
Biomarkers to Predict Toxicity Alex A Adjei
Novel Drug Development Strategies Alex A Adjei
February 17, 2008 GRC - Glycolipid & Sphingolipid Biology Inhibition of caveolar endocytosis, microdomain formation and integrin signaling by a non-natural glycosphingolipid analog Ramandeep Singh Takhter
December 1, 2007 47TH American Socieity of Cell Biology Symposium II:Architecture of Signaling Systems Marks L Richard
Stochasticity and Cell Fate Marks L Richard
Advances in Bone Cell Molecular Biology: Epigenetic Control Jennifer Westendorf
Dynamics of Rafts, Stabilized Rafts, and Other Non-Raft Domains of Mark A McNiven
October 11, 2007 Sixth International Colorectal Cancer Congress Continuous vs. Intermittent Treatment Axel Grothey
Roundtable Discussion: Should There Be Planned Chemoholidays? Axel Grothey
How Long Do We Need to Treat Patients in the Adjuvant Setting? Axel Grothey
Moving EGFR Inhibitors to the Front-line and Further: Are We Ready Yet? Axel Grothey
North Central Cancer Treatment Group Steven R. Alberts
Ongoing Clinical Trials of Antiangiogenic Agents Axel Grothey
Should Anti-VEGF Therapy Continue Beyond Progession? Axel Grothey
Neoadjuvant Therapy Options and Duration: To Best Response or Resectability? Steven R. Alberts
Biomarker-Driven Trial Designs Daniel Sargent
Have We Maxed Out the Effect of PFS in First-line Therapy? Daniel Sargent, Axel Grothey
Novel VEGFR Inhibitors in Colorectal Cancer Alex A Adjei
Multidisciplinary Management for Timing of Rectal Surgery Axel Grothey
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.